[
  {
    "ts": null,
    "headline": "Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?",
    "summary": "Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.",
    "url": "https://finnhub.io/api/news?id=a41fbce3a267d3584c748a0066f35e342597111b0424027dbc0697f9b825d867",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751313901,
      "headline": "Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?",
      "id": 135677313,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.",
      "url": "https://finnhub.io/api/news?id=a41fbce3a267d3584c748a0066f35e342597111b0424027dbc0697f9b825d867"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factory Receivetor 2B Positive First-Line Gastric",
    "summary": "Amgen announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy met its primary endpoint of overall survival at a pre-specified interim analysis....",
    "url": "https://finnhub.io/api/news?id=1efea5893ff0003044fd9c45abb7e408ebb396f91fdb5d21d26973498c387c1f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751296833,
      "headline": "Amgen Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factory Receivetor 2B Positive First-Line Gastric",
      "id": 135672409,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Amgen announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy met its primary endpoint of overall survival at a pre-specified interim analysis....",
      "url": "https://finnhub.io/api/news?id=1efea5893ff0003044fd9c45abb7e408ebb396f91fdb5d21d26973498c387c1f"
    }
  },
  {
    "ts": null,
    "headline": "AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER",
    "summary": "Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis.",
    "url": "https://finnhub.io/api/news?id=e11366e1fa87e6ffe2a76ef8ba86b57b57bd547358ef103c56dff31d0c0f80f5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751288400,
      "headline": "AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER",
      "id": 135671732,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis.",
      "url": "https://finnhub.io/api/news?id=e11366e1fa87e6ffe2a76ef8ba86b57b57bd547358ef103c56dff31d0c0f80f5"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Meets Primary Endpoint in Phase 3 Trial of Gastric Cancer Treatment",
    "summary": "By Connor Hart Amgen said a Phase 3 trial of its gastric cancer treatment, bemarituzumab, met its primary endpoint of overall survival at a pre-specified interim analysis. The biotechnology...",
    "url": "https://finnhub.io/api/news?id=9c1f2b249553b019fc2caa4ac950c33a152512fa270959ca79233705560abd62",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751277257,
      "headline": "Amgen Meets Primary Endpoint in Phase 3 Trial of Gastric Cancer Treatment",
      "id": 135652675,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "By Connor Hart Amgen said a Phase 3 trial of its gastric cancer treatment, bemarituzumab, met its primary endpoint of overall survival at a pre-specified interim analysis. The biotechnology...",
      "url": "https://finnhub.io/api/news?id=9c1f2b249553b019fc2caa4ac950c33a152512fa270959ca79233705560abd62"
    }
  },
  {
    "ts": null,
    "headline": "Amgen says gastric cancer drug meets main goal in late-stage trial",
    "summary": "Amgen said on Monday itsexperimental therapy helped patients with advanced gastriccancer live longer when combined with chemotherapy, according tointerim data from a late-stage study. ...",
    "url": "https://finnhub.io/api/news?id=af7d10b38f6edef71baaa570dd5a9bdf114bc72673ea2d773a6d7d26217b10ac",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751275510,
      "headline": "Amgen says gastric cancer drug meets main goal in late-stage trial",
      "id": 135658061,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Amgen said on Monday itsexperimental therapy helped patients with advanced gastriccancer live longer when combined with chemotherapy, according tointerim data from a late-stage study. ...",
      "url": "https://finnhub.io/api/news?id=af7d10b38f6edef71baaa570dd5a9bdf114bc72673ea2d773a6d7d26217b10ac"
    }
  },
  {
    "ts": null,
    "headline": "Amgen's gastric cancer drug meets goal in late-stage trial",
    "summary": "Amgen said on Monday itsexperimental cancer therapy significantly improved overallsurvival in patients with advanced gastric cancer when combinedwith chemotherapy, marking a potential breakthrough...",
    "url": "https://finnhub.io/api/news?id=d3254fb9cf134b7b3c86bd54940baddb577447c88aac86388703ea4933351bf9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751275510,
      "headline": "Amgen's gastric cancer drug meets goal in late-stage trial",
      "id": 135652139,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Amgen said on Monday itsexperimental cancer therapy significantly improved overallsurvival in patients with advanced gastric cancer when combinedwith chemotherapy, marking a potential breakthrough...",
      "url": "https://finnhub.io/api/news?id=d3254fb9cf134b7b3c86bd54940baddb577447c88aac86388703ea4933351bf9"
    }
  },
  {
    "ts": null,
    "headline": "Amgen's gastric cancer drug meets late-stage trial goal",
    "summary": "Amgen said on Monday itsexperimental cancer therapy, when combined with chemotherapy,met the main goal in a late-stage trial. ...",
    "url": "https://finnhub.io/api/news?id=1d3692f2f9d1874f0a778cfc6b7b6403f004dec39d5820d3398a4ddff6a339f1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751274444,
      "headline": "Amgen's gastric cancer drug meets late-stage trial goal",
      "id": 135651829,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Amgen said on Monday itsexperimental cancer therapy, when combined with chemotherapy,met the main goal in a late-stage trial. ...",
      "url": "https://finnhub.io/api/news?id=1d3692f2f9d1874f0a778cfc6b7b6403f004dec39d5820d3398a4ddff6a339f1"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Stocks to Buy on the Dip and Hold Forever",
    "summary": "Apple and Amgen have faced company-specific issues over the past 12 months.  Over the past year, Apple (NASDAQ: AAPL) and Amgen (NASDAQ: AMGN), two well-established companies that are part of the iconic Dow Jones Industrial Average, have faced significant headwinds.  Apple is struggling due to the threat that President Donald Trump's trade agenda poses to its business, while Amgen faced a clinical setback late last year.",
    "url": "https://finnhub.io/api/news?id=f5a42c3b88f6f8792825edf3c8faa9634390c9f9ed88a84ff2a2e56c723faabb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751274300,
      "headline": "2 Dividend Stocks to Buy on the Dip and Hold Forever",
      "id": 135671197,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Apple and Amgen have faced company-specific issues over the past 12 months.  Over the past year, Apple (NASDAQ: AAPL) and Amgen (NASDAQ: AMGN), two well-established companies that are part of the iconic Dow Jones Industrial Average, have faced significant headwinds.  Apple is struggling due to the threat that President Donald Trump's trade agenda poses to its business, while Amgen faced a clinical setback late last year.",
      "url": "https://finnhub.io/api/news?id=f5a42c3b88f6f8792825edf3c8faa9634390c9f9ed88a84ff2a2e56c723faabb"
    }
  }
]